Literature DB >> 31871075

Long-Term Compassionate Use of Cefiderocol To Treat Chronic Osteomyelitis Caused by Extensively Drug-Resistant Pseudomonas aeruginosa and Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae in a Pediatric Patient.

Zain I Alamarat1, Jessica Babic2, Truc T Tran3,4, Susan H Wootton1, An Q Dinh3,4, William R Miller3,4,5, Blake Hanson3,4,5, Audrey Wanger6, Joshua L Gary7, Cesar A Arias3,4,5,8,9, Norma Pérez10.   

Abstract

We report a 15 year-old Nigerian adolescent male with chronic osteomyelitis caused by an extensively drug-resistant (XDR) Pseudomonas aeruginosa strain of sequence type 773 (ST773) carrying bla NDM-1 and an extended spectrum β-lactamase (ESBL)-producing Klebsiella pneumoniae strain. The patient developed neurological side effects in the form of circumoral paresthesia with polymyxin B and asymptomatic elevation of transaminases with aztreonam (used in combination with ceftazidime-avibactam). Cefiderocol treatment for 14 weeks plus bone implantation resulted in apparent cure and avoided amputation.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  ESBL-producing Klebsiella pneumoniae; XDR Pseudomonas aeruginosa; cefiderocol; chronic osteomyelitis; pediatric

Year:  2020        PMID： 31871075      PMCID： PMC7179260          DOI： 10.1128/AAC.01872-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and Enterobacteriaceae with Defined Extended-Spectrum β-Lactamases and Carbapenemases.

Authors:  Michael R Jacobs; Ayman M Abdelhamed; Caryn E Good; Daniel D Rhoads; Kristine M Hujer; Andrea M Hujer; T Nicholas Domitrovic; Susan D Rudin; Sandra S Richter; David van Duin; Barry N Kreiswirth; Chris Greco; Derrick E Fouts; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

2.  A multiresistant clone of Pseudomonas aeruginosa sequence type 773 spreading in a burn unit in Orumieh, Iran.

Authors:  Saber Yousefi; Mohammad Reza Nahaei; Safar Farajnia; Mohammad Aghazadeh; Aina Iversen; Petra Edquist; Makaoui Maãtallah; Christian G Giske
Journal:  APMIS       Date:  2012-07-17       Impact factor: 3.205

3.  In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan.

Authors:  Shun-Chung Hsueh; Yuarn-Jang Lee; Yu-Tsung Huang; Chun-Hsing Liao; Masakatsu Tsuji; Po-Ren Hsueh
Journal:  J Antimicrob Chemother       Date:  2019-02-01       Impact factor: 5.790

4.  Multiyear, Multinational Survey of the Incidence and Global Distribution of Metallo-β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa.

Authors:  Krystyna M Kazmierczak; Sharon Rabine; Meredith Hackel; Robert E McLaughlin; Douglas J Biedenbach; Samuel K Bouchillon; Daniel F Sahm; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2015-12-07       Impact factor: 5.191

5.  Acquired qnrVC1 and blaNDM-1 resistance markers in an international high-risk Pseudomonas aeruginosa ST773 clone.

Authors:  Bela Kocsis; Akos Toth; Daniel Gulyas; Balazs Ligeti; Katalin Katona; Laszlo Rokusz; Dora Szabo
Journal:  J Med Microbiol       Date:  2019-01-22       Impact factor: 2.472

6.  International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP).

Authors:  Brian T Tsuji; Jason M Pogue; Alexandre P Zavascki; Mical Paul; George L Daikos; Alan Forrest; Daniele R Giacobbe; Claudio Viscoli; Helen Giamarellou; Ilias Karaiskos; Donald Kaye; Johan W Mouton; Vincent H Tam; Visanu Thamlikitkul; Richard G Wunderink; Jian Li; Roger L Nation; Keith S Kaye
Journal:  Pharmacotherapy       Date:  2019-01       Impact factor: 6.251

7.  Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against Pseudomonas aeruginosa.

Authors:  Akinobu Ito; Toru Nishikawa; Shuhei Matsumoto; Hidenori Yoshizawa; Takafumi Sato; Rio Nakamura; Masakatsu Tsuji; Yoshinori Yamano
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

8.  CARD 2017: expansion and model-centric curation of the comprehensive antibiotic resistance database.

Authors:  Baofeng Jia; Amogelang R Raphenya; Brian Alcock; Nicholas Waglechner; Peiyao Guo; Kara K Tsang; Briony A Lago; Biren M Dave; Sheldon Pereira; Arjun N Sharma; Sachin Doshi; Mélanie Courtot; Raymond Lo; Laura E Williams; Jonathan G Frye; Tariq Elsayegh; Daim Sardar; Erin L Westman; Andrew C Pawlowski; Timothy A Johnson; Fiona S L Brinkman; Gerard D Wright; Andrew G McArthur
Journal:  Nucleic Acids Res       Date:  2016-10-26       Impact factor: 16.971

9.  Compassionate Use of Cefiderocol as Adjunctive Treatment of Native Aortic Valve Endocarditis Due to Extremely Drug-resistant Pseudomonas aeruginosa.

Authors:  Jonathan D Edgeworth; Domenico Merante; Sanjay Patel; Christopher Young; Paul Jones; Seema Vithlani; Duncan Wyncoll; Peter Roberts; Andrew Jones; Tsutae Den Nagata; Mari Ariyasu; David M Livermore; Richard Beale
Journal:  Clin Infect Dis       Date:  2019-05-17       Impact factor: 9.079

10.  Extensively Drug-Resistant Pseudomonas aeruginosa ST309 Harboring Tandem Guiana Extended Spectrum β-Lactamase Enzymes: A Newly Emerging Threat in the United States.

Authors:  Ayesha Khan; Truc T Tran; Rafael Rios; Blake Hanson; William C Shropshire; Zhizeng Sun; Lorena Diaz; An Q Dinh; Audrey Wanger; Luis Ostrosky-Zeichner; Timothy Palzkill; Cesar A Arias; William R Miller
Journal:  Open Forum Infect Dis       Date:  2019-06-06       Impact factor: 3.835
View more
  12 in total

1.  Case Commentary: the Need for Cefiderocol Is Clear, but Are the Supporting Clinical Data?

Authors:  Ryan K Shields
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

Review 2.  New Perspectives on Antimicrobial Agents: Cefiderocol.

Authors:  Erin K McCreary; Emily L Heil; Pranita D Tamma
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

3.  Cefiderocol for treatment of an empyema due to extensively drug-resistant Pseudomonas aeruginosa: Clinical observations and susceptibility testing considerations.

Authors:  Wesley D Kufel; Jeffrey M Steele; Scott W Riddell; Zachary Jones; Pegah Shakeraneh; Timothy P Endy
Journal:  IDCases       Date:  2020-06-03

Review 4.  Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data.

Authors:  Daniele Roberto Giacobbe; Eugenio Ciacco; Corrado Girmenia; Federico Pea; Gian Maria Rossolini; Giovanni Sotgiu; Carlo Tascini; Mario Tumbarello; Pierluigi Viale; Matteo Bassetti
Journal:  Infect Drug Resist       Date:  2020-12-29       Impact factor: 4.003

5.  Compassionate use of cefiderocol for carbapenem-resistant Acinetobacter baumannii prosthetic joint infection.

Authors:  Diana A Mabayoje; Caoimhe NicFhogartaigh; Benny P Cherian; Mei Gie Meiqi Tan; David W Wareham
Journal:  JAC Antimicrob Resist       Date:  2021-06-15

6.  Education: A compassionate use of cefiderocol to treat osteomyelitis caused by an XDR Pseudomonas aeruginosa.

Authors:  A Chavda; M Gilchrist; D Samarasinghe
Journal:  JAC Antimicrob Resist       Date:  2021-06-15

7.  Case Report: Successful Rescue Therapy of Extensively Drug-Resistant Acinetobacter baumannii Osteomyelitis With Cefiderocol.

Authors:  Michael Dagher; Felicia Ruffin; Steven Marshall; Magdalena Taracila; Robert A Bonomo; Rachel Reilly; Vance G Fowler; Joshua T Thaden
Journal:  Open Forum Infect Dis       Date:  2020-05-05       Impact factor: 4.423

8.  Cefiderocol for Extensively Drug-Resistant Gram-Negative Bacterial Infections: Real-world Experience From a Case Series and Review of the Literature.

Authors:  Sandra Zingg; G Jacopo Nicoletti; Sabine Kuster; Milena Junker; Andreas Widmer; Adrian Egli; Vladimira Hinic; Parham Sendi; Manuel Battegay; Veronika Bättig; Nina Khanna; Sarah Tschudin-Sutter
Journal:  Open Forum Infect Dis       Date:  2020-05-21       Impact factor: 3.835

9.  Antibiotic Resistant Bloodstream Infections in Pediatric Patients Receiving Chemotherapy or Hematopoietic Stem Cell Transplant: Factors Associated with Development of Resistance, Intensive Care Admission and Mortality.

Authors:  Elio Castagnola; Francesca Bagnasco; Alessio Mesini; Philipp K A Agyeman; Roland A Ammann; Fabianne Carlesse; Maria Elena Santolaya de Pablo; Andreas H Groll; Gabrielle M Haeusler; Thomas Lehrnbecher; Arne Simon; Maria Rosaria D'Amico; Austin Duong; Evgeny A Idelevich; Marie Luckowitsch; Mariaclaudia Meli; Giuseppe Menna; Sasha Palmert; Giovanna Russo; Marco Sarno; Galina Solopova; Annalisa Tondo; Yona Traubici; Lillian Sung
Journal:  Antibiotics (Basel)       Date:  2021-03-05

10.  An Evidence-Based Multidisciplinary Approach Focused on Creating Algorithms for Targeted Therapy of Infection-Related Ventilator-Associated Complications (IVACs) Caused by Pseudomonas aeruginosa and Acinetobacter baumannii in Critically Ill Adult Patients.

Authors:  Milo Gatti; Bruno Viaggi; Gian Maria Rossolini; Federico Pea; Pierluigi Viale
Journal:  Antibiotics (Basel)       Date:  2021-12-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.